|Dr. Jingwu Zhang Zang M.D., Ph.D.||Founder & Chairman||N/A||N/A||1956|
|Dr. Andrew X. Zhu M.D., Ph.D.||Member of Scientific Advisory Board, Pres, Acting CEO & Director||N/A||N/A||1960|
|Dr. Jerry Wang||Co-Founder & Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Richard L. Yeh M.B.A.||Interim CFO, COO & Director||N/A||N/A||1968|
|Mr. Tianyi Zhang||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Cheng Li||Chief Legal Officer||N/A||N/A||1984|
|Ms. Gigi Qi Feng||Chief Communications Officer||N/A||N/A||1981|
|Dr. Weiming Tang Ph.D.||Exec. VP of Global Bus. Devel. & Chief Bus. Officer||N/A||N/A||1966|
|Dr. Fernando J. Salle´s Ph.D.||Sr. VP and Head of U.S. & EU Bus. Devel.||N/A||N/A||N/A|
|Mr. Ivan Yifei Zhu||Chief Commercial Officer||N/A||N/A||1969|
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
I-Mab’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.